Hengrui Medicine: SHR-3836 Injection Approved for Clinical Trials.

On March 20th, Hengrui Medicine announced that its subsidiary, Shanghai Hengrui Medicine Co., Ltd., received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration for the SHR-3836 injection. The approval allows the drug to be tested as a single agent in clinical trials for multiple myeloma.